The Immune Tolerance Network

The Immune Tolerance Network (ITN) is an international clinical research consortium sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). ITN's mission is to advance the clinical application of immune tolerance therapies and biomarker development by performing high quality clinical trials of emerging therapeutics integrated with mechanism-based research.

ITN TrialShare is a clinical trials research web portal developed to share information about ITN's clinical studies and specimen bio-repository with the scientific community. Data and analysis code underlying ITN-published manuscripts are made publicly available via TrialShare with the goal of promoting transparency, reproducibility, scientific collaboration and more rapid advancement of the field. The ITN also has thousands of biological specimens from clinically well-phenotyped study participants that are available for investigators to request for their own research. Below is a list of the studies currently available to the public on ITN TrialShare.

Public Studies on ITN TrialShare

Transplant

Liver

  • Primary Investigator: Feng A prospective multicenter, open-label, single-arm trial in which 20 pediatric recipients of parental living-donor liver allografts undergo gradual withdrawal of immunosuppression with the goal of complete withdrawal

    Manuscripts and Abstracts

    • Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 307: 283-293, 2012. Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, Alonso EM, Philogene MC, Ikle D, Poole KM, Bridges ND, Turka LA, Tchao NK
    • Quality assessments of un-gated flow cytometry FCS files in a clinical trial setting XXV Congress of the International Society for the Advancement of Cytometry, Seattle, WA Lim N, Kanaparthi S, Mertens S, Gopalakrishnan N, Gao Z, Liu Z, Bourcier K, Phippard D, Asare A
    • ITN029ST: Immunosuppression Withdrawal in Pediatric Recipients of Parental Living Donor Liver Transplants: Preliminary Results of a Pilot Study American Transplant Congress, Boston, MA Feng S, Ekong U, Lobritto S, Demetris A, Rosenthal P, Alonso E, Tchao N
    • A high throughput approach to quality assessment of un-gated, clinical flow cytometric immunophenotyping data Federation of Clinical Immunology Societies (FOCIS), Boston, MA Kanaparthi S, Lim N, Mertens S, Gopalakrishnan N, Liu Z, Bouricer K, Phippard D, Asare A
    • Prospective evaluation of histopathology biopsy features that predict successful weaning and comparison to protocol follow-up biopsies 2 years after complete immunosuppression withdrawal in living-related pediatric liver allograft recipients American Association for the Study of Liver Diseases (AASLD), Boston, MA Demetris AJ, Ruppert K, Ekong U, Lobritto SJ, Tchao NK, Feng S
    • Clinical and histological predictors of operational tolerance in pediatric liver transplant recipients The 2011 Joint International Congress of ILTS, ELITA, & LICAGE, Valencia, Spain Feng S, Ekong U, Lobritto S, Demetris A, Rosenthal P, Alonso E, Philogene M, Ikle D, Phippard D, Tchao N
    MeSH tags (Click to show/hide)

Kidney

  • Primary Investigator: Newell A registry trial collecting extensive demographic and clinical information, medical histories, and blood and urine samples of tolerant kidney transplant recipients.

    Manuscripts and Abstracts

    • Identification of a B cell signature associated with renal transplant tolerance in humans J Clin Invest 120: 1836-1847, 2010 Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, Hernandez-Fuentes MP, Turka LA, Seyfert-Margolis VL
    • Donor-specific indirect pathway analysis reveals a B-cell independent signature which reflects outcomes in kidney transplant recipients Am J Transplant 12: 640-648, 2011 Haynes LD, Jankowska-Gan E, Sheka A, Keller MR, Hernandez-Fuentes MP, Lechler RI, Seyfert-Margolis V, Turka LA, Newell KA, Burlingham WJ
    • Peripheral B Cell Markers Identify Tolerant Renal Transplant Recipients (Abstract #LB08) American Transplant Congress, Boston, MA, May 30 - Jun 3, 2009 Newell KA, Asare A, Kirk AD, Suthanthiran M, Burlingham WJ, Bourcier K, Marks WH, Turka LA, Seyfert-Margolis V, Gisler T
    • Preliminary Analysis of the ITN Registry of Tolerant Kidney Transplant Recipients World Transplant Congress, Boston, MA, July 22 – 27, 2006 Newell KA, Burlingham WJ, Marks WH, Gisler TD, Seyfert VL, Turka LA, Suthanthiran M, Kirk AD
    • Donor Specific Regulation and B Cell Tolerance Signature in Renal Transplant Recipients (Abstract #1578) 2010 American Transplant Congress, San Diego, CA, May 1-5, 2010 Haynes LD, Jankowska-Gan E, Seyfert-Margolis VL, Newell KA, Turka LA, Asare A, Burlingham WJ, Bourcier KD
    • A Unique B cell Signature Associated with Operational Tolerance American Transplant Congress, Toronto, Canada, May 31-Jun 4, 2008 Newell KA, Asare A, Gisler T, Turka L, Seyfert-Margolis V, Suthanthiran MS, Burlingham W, Marks W
    • Refinements of the transcriptional B cell "signature" associated with clinically tolerant renal transplant recipients (Abstract #252659) American Transplant Congress, Boston, MA, June 2-6, 2012 Newell KA, Phippard D, Asare A, Burlingham WJ, Turka LA
    MeSH tags (Click to show/hide)
  • Manuscripts and Abstracts

    • HLA-mismatched renal transplantation without maintenance immunosuppression New Eng L Med. 368: 1850-1852, 2013 Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DS, Hertl M, Goes NB, Wong W, Williams WW Jr, Colvin RB, Sykes M, Sachs DH
    • B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans Am J Transplant 9: 2126-35, 2009 Porcheray F, Wong W, Saidman SL, De Vito J, Girouard TC, Chittenden M, Shaffer J, Tolkoff-Rubin N, Dey BR, Spitzer TR, Colvin RB, Cosimi AB, Kawai T, Sachs DH, Sykes M, Zorn E
    • HLA-mismatched renal transplantation without maintenance immunosuppression N Engl J Med 358: 353-61, 2008 Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DS, Hertl M, Goes NB, Wong W, Williams WW Jr, Colvin RB, Sykes M, Sachs DH
    MeSH tags (Click to show/hide)
  • Primary Investigator: Miller-Burke Pilot Study Using Donor Stem Cells and Campath - 1H to Induce Renal Transplant Tolerance

    Manuscripts and Abstracts

    • Circulating and graft infiltrating regulatory cells in donor stem cell infused kidney transplant patients treated with alemtuzumab 12th Innovative Therapeutics in Transplantation Meeting, Nantes, France, June 15, 2006 Mathew J, Carreno M, Cirocco R, Rosen A, Vallone T, Garcia-Morales R, Burke GW, Ciancio G, Esquenazi V, Miller J
    • Regulatory cells of donor and recipient phenotypes in donor stem cell infused kidney transplant recipients treated with alemtuzumab World Transplant Congress, Boston, MA, July 22-27, 2006 Mathew J, Vallone T, Carreno M, Garcia-Morales R, Rosen A, Gomez C, Burke GW, Ciancio G, Esquenazi V, Miller J, Blomberg B, Fuller L
    • Tolerogenicity of graft infiltrating lymphocytes in donor stem cell infused kidney transplant recipients treated with alemtuzumab ASHI 31st Annual Meeting, San Diego, CA, October 17, 2006 Mathew J, Cirocco R, Rosen A, Vallone T, Gomez C, Blomberg B, Fuller L, Burke GW, Ciancio G, Esquenazi V, Miller J
    • Upregulation of FOXP3 in renal transplantation after antibody induction regimens with and without bone marrow or stem cell infusions World Transplant Congress, Boston, MA, July 22-27, 2006 Cirocco R, Carreno M, Mathew J, Vallone T, Rosen A, Burke GW, Ciancio G, Esquenazi V, Miller J, Kleiner G
    • Comparative chimerism levels in cadaver and living related donor whole bone marrow infused kidney recipients vs. a 2X stem cell-infused recipient treated with alemtuzumab Basic Science Symposium of the International Transplantation Society, La Baule, France, June 19-23, 2005 Esquenazi V, Kleiner G, Burke GW, Ciancio G, Ricordi C, Garcia-Morales RO, Cirocco RE, Carreno MR, Kenyon NS, Tzakis AG, Shariatmadar S, Miller J
    • Regulatory cell development in an LRD-kidney transplant recipient treated with alemtuzumab and donor stem cell infusions (ITN protocol) ASHI 31st Annual Meeting, Washington, DC, Oct 17-21, 2005 Vallone T, Carreno M, Rosen A, Gomez C, Garcia-Morales R, Blomberg B, Fuller L, Ciancio G, Esquenazi V, Miller J, Mathew JM, Burke G
  • Manuscripts and Abstracts

    • Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring American Journal of Transplantation 9: 1087-1098, 2009 Knechtle SJ, Pascual J, Bloom DD, Torrealba JR, Jankowska-Gan E, Burlingham WJ, Kwun J, Colvin RB, Seyfert-Margolis V, Bourcier K, Sollinger HW
    • 4 Yr Follow-Up of an ITN-Sponsored, Alemtuzimab-Based Tolerance Induction Trial: Donor-Specific Regulation [DSR] Identifies Renal Transplants with Superior Outcome 2010 American Transplant Congress, San Diego, CA, May 1-5, 2010 (Abstract #1563) Burlingham WJ, Jankowska-Gan E, Gawin D, Haynes L, Knechtle S, Djamali A
    • Sirolimus monotherapy in kidney transplantation: Results of an ITN-sponsored trial American Transplant Congress, Toronto, Canada, May 31-Jun 4, 2008 (Abstract #134) Knechtle S, Pascual J, Jankowska-Gan E, Bourcier K, Seyfert-Margolis V, Burlingham W, Bloom D, Torrealba J, Harper L, Colvin R, Sollinger H
    • A Tolerance Trial in Kidney Transplantation Based on T-cell Depletion, Tacrolimus, and Sirolimus American Transplant Congress, San, May 5-9, 2007 Knechtle S, Sollinger H, Bloom D, Hu H, Janus C, Radke N, Davis Z
    • Preliminary results of a tolerance trial in renal transplantation World Transplant Congress, Boston, MA, July 22-27, 2006 Knechtle SJ, Sollinger HW, Jankowska-Gan E, Burlingham WJ, Bloom DJ

Autoimmune

ANCA-Associated Vasculitis

  • Primary Investigator: Specks-Stone Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-associated Vasculitis

    Manuscripts and Abstracts

    • Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis New Eng J Med 2013; 369:417-427 Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Fessler BJ, Ding L, Viviano L, Tchao NK, Phippard DJ, Asare AL, Lim N, Ikle D, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Mueller M, Sejismundo LP, Mieras K, Stone JH.
    • Circulating markers of vascular injury and angiogenesis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheum 63: 3988-3997, 2011 Monach PA, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Ding L, Fervenza FC, Fessler BJ, Hoffman GS, Ikle D, Kallenberg CG, Langford CA, Mueller M, Seo P, St Clair EW, Spiera R, Tchao N, Ytterberg SR, Gu YZ, Snyder RD, Merkel PA
    • Design of the Rituximab in ANCA-associated Vasculitis (RAVE) Trial. The Open Arthritis Journal: 4, 1-18, 2011 Specks U, Merkel PA, Hoffman GS, Langford CA, Spiera R, Seo P, Kallenberg CGM, St. Clair EW, Ding L, Webber L, Mokhtarani M, Tchao NK, Sayre PH, Seyfert-Margolis V, Ikle D, Brunetta P, Zhang D, Sejismundo L, Mueller M, Stone JH.
    • Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis New Eng J Med 363: 221-232, 2010 Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U.
    • Circulating angiopoietin-2 as a biomarker in ANCA-associated Vasculitis. Plos One 7(1): e30197, 2012 Monach PA, Kümpers P, Lukasz A, Tomasson G, Specks U, Stone JH, Cuthbertson D, Krischer J, Carette S, Ding L, Hoffman GS, Iklé D, Kallenberg CG, Khalidi NA, Langford CA, Seo P, St Clair EW, Spiera R, Tchao N, Ytterberg SR, Haubitz M, Merkel PA
    • Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis: Which Subsets Are At Greatest Risk for Flare? . American College of Rheumatology, Chicago, IL, November 4-9, 2011. Stone JH, Merkel PA, Seo P, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Tchao N, Webber L, Ding L, Sejismundo LP, Mieras K, Ikle D, Asare A, Lim N, Mueller M, Brunetta P, Allen NB, Specks U, Spiera RF, Fessler BJ, Phippard DJ, Jepson B, Lail A, Fervenza F, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, RAVE-ITN Research Group.
    • Serum Proteins Reflecting Inflammation, Injury, and Repair As Biomarkers of Disease Activity in ANCA-Associated Vasculitis . American College of Rheumatology, Chicago, IL, November 4-9, 2011. Monach PA, Specks U, Stone JH, Ding L, Fervenza F, Fessler BJ, Hoffman GS, Ikle D, Kallenberg CGM, Langford CA, Mueller M, Seo P, St. Clair EW, Spiera RF, Tchao N, Ytterberg SR, Warner RL, Tomasson G, Krischer J, Johnson KJ, Merkel PA.
    • Rituximab for ANCA-associated Vasculitis (RAVE) Trial. 14th Int'l Vasculitis and ANCA Workshop, Lund, Sweden, 6-9 June, 2009. Stone JH, Specks U, ITN RAVE (ITN021AI) Study Group.
    • Immunoglobulin Concentrations and Infection Risk Among Patients with ANCA-Associated Vasculitis Treated with Rituximab or Cyclophosphamide. American College of Rheumatology, Chicago, IL, November 4-9, 2011. Specks U, Merkel PA, Seo P, Spiera RF, Langford CA, Hoffman GS, Kallenberg CGM, St. Clair EW, Brunetta P, Tchao N, Fessler BJ, Webber L, Ding L, Sejismundo LP, Mieras K, Phippard DJ, Asare A, Lim N, Ikle D, Jepson B, Lail A, Tole S, Shen S, Mueller M.
    • The Efficacy of Rituximab Vs Cyclophosphamide for Treatment of Renal Disease in ANCA-Associated Vasculitis: The RAVE Trial. American College of Rheumatology Annual Meeting, Washington, DC Geetha D, Fervenza FC for the RAVE-ITN Research Group
    • The Efficacy of Rituximab versus Cyclophosphamide for Treatment of Renal Disease in ANCA-associated Vasculitis: The RAVE Trial American Society of Nephrology (ASN) Kidney Week, San Diego, CA Geetha D, Fervenza FC, RAVE-ITN Group
    • Primary Endpoint Failure in the Rituximab in ANCA-Associated Vasculitis Trial American College of Rheumatology (ACR) Annual Meeting, Washington, DC Specks U, Stone JH, Miloslavsky E, and the RAVE-ITN Research Group
    • Predictive value of selected markers of inflammation and platelet activation for complete remission in ANCA-associated Vasculitis American College of Rheumatology (ACR) Annual Meeting, Washington, DC Tomasson G, Monach PA, Specks U, Stone JH, Ding L, Fervenza F, Hoffman GS, Kallenberg CGM, Langford CA, Phippard DJ, Seo P, Spiera RF, St. Clair EW, Tchao N, Merkel PA, Tanriverdi K, Freedman JE
    MeSH tags (Click to show/hide)

Multiple Sclerosis

  • Manuscripts and Abstracts

    • Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study Neurology. 78: 1171-1178, 2012 Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; ITN STAyCIS Study Group; ITN020AI Study Management Team
    • Atorvastatin therapy in patients with Clinically Isolated Syndrome (CIS): the STAyCIS study 134th Annual Meeting, American Neurological Assocation, Baltimore, MD Waubant E, Pelletier D, Mass M, Cohen J, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi P, Miller A, Mokhtarani M, Ikle D, Ding L, Rosenberg E, ITN020AI Study Management Team, Spencer C, Zamvil SS
    • Atorvastatin therapy in patients with Clinically Isolated Syndrome (CIS) and High Risk for Conversion to Multiple Sclerosis (MS): the STAyCIS study ECTRIMS, Dusseldorf, Germany Emmanuelle Waubant, Daniel Pelletier, Michele Mass, Jeff Cohen, Mariko Kita, Anne Cross, Amit Bar-Or, Timothy Vollmer, Michael Racke, Olaf Stuve, Steven Schwid, Andrew Goodman, Norman Kachuck, Jana Preiningerova, Bianca Weinstock-Guttman, Peter Calabresi, Aaron Miller, Masoud Mokhtarani, David Iklé, Linna Ding, Ellen Rosenberg, ITN020AI Study Management Team, Collin Spencer, Scott S. Zamvil
    • Atorvastatin reduces the risk of new brain MRI lesions in patients with Clinically Isolated Syndrome (CIS) compared to placebo 62nd Annual Meeting of the American Academy of Neurology, Toronto, Canada Mokhtarani M, Ikle D, Ding L, Waubant E, Pelletier D, Mass M, Cohen J, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi P, Miller A, Rosenberg E, ITN020AI Study Managem
    MeSH tags (Click to show/hide)
  • Manuscripts and Abstracts

    • T cell repertoire following autologous stem cell transplantation for multiple sclerosis J Clin Invest. 2014 Muraro PA, Robins H, Malhotra S, Howell M, Phippard D, Desmarais C, de Paula Alves Sousa A, Griffith LM, Lim N, Nash RA, Turka LA.
    • Treatment of Severe Relapsing-Remitting Multiple Sclerosis with High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation: Early Results of the HALT MS Clinical Trial American Society of Hematology, San Diego, CA Nash RA, Hutton GJ, Racke MK, Griffith LM, Muraro PA, Stüve O, Wundes A, Kraft GH, Popat UR, Devine SM, Openshaw J, Sayre PH, Arnold DL, Wruck L, Bowen JD
    • HALT MS - Phase II Clinical Trial of High Dose Immunosuppressive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Active Relapsing-Remitting Multiple Sclerosis 2009 Annual Meeting of the American Academy of Neurology, Tuczon, AZ Bowen JD, Sayre P, Stüve O, Wundes A, Kraft GH, Hutton GJ, Openshaw H, Forman SJ, Frohman EM, Griffith LM, Muraro PA, Racke MK, Popat U, Nash RA
    • HALT-MS—Intense Immunosuppression and Stem Cell Transplantation for RRMS 23rd Annual Meeting of the Consortium of MS Centers, Atlanta, GA Hutton GJ, Bowen JD, Forman SJ, Frohman EM, Griffith LM, Kraft GH, Openshaw H, Popat U, Racke M, Sayre P, Stüve O, Wundes A, Nash RA, Muraro P
    • Phase II clinical trial (HALT MS: Immune Tolerance Network) of high dose immunosuppressive therapy (HDIT) and autologous hematopoietic stem cell transplantation (AHSCT) for active relapsing-remitting (RR) multiple sclerosis (MS): Early results American Academy of Neurology, Chicago, IL Kraft GH, Bowen JD, Openshaw H, Forman SJ, Frohman EM, Griffith LM, Hutton GJ, Muraro PA, Popat U, Racke MK, Sayre P, Stüve O, Wundes A, Nash RA
    • A Phase II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+ Hematopoietic Stem Cell Transplant (HCT) for treatment of poor prognosis MS: HALT-MS 22nd Annual Meeting of the CMSC, Denver, CO Nash RA, Openshaw H, Bowen JD, Forman SJ, Stüve O, Popat U, Hutton G, Kraft G
  • Manuscripts and Abstracts

    • CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial Neurology 71: 917-924, 2008 Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ
    • Phase I trial of CTLA4Ig treatment in MS 56th American Academy of Neurology, San Francisco, CA Khoury SJ, Bourcier K, Buckle G, Bikowski M, Guttmann C, Rioux P, Jauregui K
    • A Phase I Trial of CTLA4Ig Treatment in MS 57th Annual Meeting of the American Academy of Neurology, Miami Beach, FL Khoury SJ, Viglietta V, Hafler D, Bourcier K, Buckle G, Guttmann C, Bikowski M, Rusche J, Landy H, McNally J, Jauregui K
    MeSH tags (Click to show/hide)

Type I Diabetes

  • Primary Investigator: Greenbaum A phase I, single-arm, open-label trial using IL-2 and Sirolimus in individuals with recent-onset T1DM to halt autoimmune destruction of remaining beta cells

    Manuscripts and Abstracts

    • Rapamycin/IL-2 combination therapy in patients with Type 1 Diabetes augments Tregs yet transiently impairs beta-cell function Diabetes. 61: 2340-2348, 2012 Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ
    • Rapamycin plus IL-2 combination therapy in subjects with T1D results in a sustained increase in IL-2 responsiveness and a transient decrease in C-peptide levels American Diabetes Association - 71st Scientific Sessions San Diego, CA, June 24-28, 2011 Long SA, Sanda S, Goland R, Bianchine P, Phippard D, Ehlers M, Greenbaum C, Buckner JH, Bollyky JB
    • Marked Differences in T Cell Reactivity in Recently Diagnosed Type 1 Diabetes Patients Versus Controls XXIIth International Congress of Immunology- Montreal, Canada, July 18-23, 2004 Dosch HM, Syfert V, Greenbaum CJ, Gitelman SE, Palmer JP, Brooks-Worrell BM, Herold K
    • Rapamycin plus IL-2 combination therapy in T1D subjects enhances IL-1 responsivesness in CD25+ Treg, but also NK and effector T cells Federation of Clinical Immunology Societies (FOCIS), Washington, DC Phippard D, Long SA, Rieck M, Sanda S, Bollyky J, Goland R, Bianchine P, Ehlers M, Greenbaum C, Buckner J
    MeSH tags (Click to show/hide)
  • Primary Investigator: Herold A Phase II Multiple-Dose Treatment of Type 1 Diabetes Mellitus With hOKT3gamma1 (Ala-Ala)

    Manuscripts and Abstracts

    • Treatment with hOKT3?1(Ala-Ala) improves insulin responses and reduces insulin requirements in patients with new onset Type 1 diabetes (T1DM) 64th Scientific Sessions of the American Diabetes Association, Orlando, FL Herold K, Gitelman S, Masharani U, Greenbaum C, Hagopian W, Gottlieb P, Ramos E, Bluestone JA, Muir A, Tomilin N
    • Treatment with hOKT3?1(Ala-Ala) improves insulin responses and reduces insulin requirements in patients with new onset Type 1 diabetes (T1DM) XXIIth International Congress of Immunology, Montreal, Canada Herold K, Gitelman S, Masharani U, Greenbaum C, Hagopian W, Gottlieb P, Muir A, Ramos E, Bluestone JA, Tomlin N
    • Immune monitoring: the effects of hOKT3?1 (Ala-Ala) in a patient with new onset type 1 diabetes mellitus Meeting of the Federation of Clinical Immunology Societies, Boston, MA Herold KC, Gitelman SE, Liu WH, Szot G, Earle KE, Masharani U, Bluestone JA
    • Metabolic parameters at baseline identify clinical responders to teplizumab 2 years after diagnosis of type 1 diabetes European Association for the Study of Diabetes, Berlin, Germany Herold KC, Ehlers M, McNamara J, Gitelman S, Gottlieb P, Hagopian W, Bluestone JA, Boyle K, Greenbaum, C
    • Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders Diabetes. 2013 Nov;62(11):3766-74 Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; the AbATE Study Team
  • Primary Investigator: Shapiro An open-label, multi-center feasibility study with to establish that the Edmonton protocol results may be replicated at other sites.

    Manuscripts and Abstracts

    • International trial of the Edmonton protocol for islet transplantation New Engl J Med 355: 1318-1330, 2006 Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR
    • Portal vein thrombosis complicating islet transplantation in a recipient with the Factor V Leiden mutation Transplantation 78:172-3, 2004 Brennan DC, Shannon MB, Koch MJ, Polonsky KS, Desai N, Shapiro J
    • International multicenter trial of islet transplantation using the Edmonton protocol in patients with type 1 diabetes American Transplant Congress, Washington, DC, May 30 - Jun 4, 2003 (Abstract #3) Ricordi C, DiMercurio B, Lindblad R, Cagliero E, Robertson RP, Berney T, Ramos E, Viviano L, Shapiro J, Hering B, Brendel M, Oberholzer J, Secchi A, Brennan D, Ryan E, Lakey J
    • Standardization of human islet isolation for an international multi-center transplant trial American Transplant Congress, Washington, DC, May 30 - Jun 4, 2003 (Abstract #571) Ricordi C, Hering B, DiMercurio B, Lindblad R, Bertuzzi F, Oberholzer J, Ramos E, Viviano L, Shapiro AMJ, Lakey JRT, O'Neil J, Olack B, Reems JA, Ansite J, Kirlew T, Brandhorst H, Bucher P
    MeSH tags (Click to show/hide)
  • Manuscripts and Abstracts

    • Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy J Autoimmun. 34: 408-415, 2010 Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, Reijonen H, Wolfsdorf J, Ricker A, Matthews JB, Tchao N, Sayre P, Bianchine P
    MeSH tags (Click to show/hide)
  • Manuscripts and Abstracts

    • Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial The Lancet Diabetes & Endocrinology, 28 August 2013; doi:10.1016/S2213-8587(13)70065-2. Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, the START Study Team
    • Effect of anti-thymocyte globulin (ATG) on preserving beta cell function in new-onset type 1 diabetes European Association for the Study of Diabetes, Berlin, Germany, October 1-5, 2012 (Abstract #454) Gitelman SE, Gottlieb PA, Rigby MR, Willi SM, Ding L, Ehlers MR, Fisher LK, Gottschalk M, Moore WV, Moran A, Keyes-Elstein L, Pinckney A, START Study Team

Allergy

Ragweed

  • Manuscripts and Abstracts

    • Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding J Allergy Clin Immunol 120: 688-95, 2007 Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN
    • Omalizumab Pretreatment Decreases Acute Reactions Following Rush Immunotherapy for Ragweed-Induced Seasonal Allergic Rhinitis J Allergy Clin Immunol 117: 134-140, 2006 Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y, Immune Tolerance Network
    • Omalizumab Plus Rush Immunotherapy (RIT) Is More Effective Than RIT Alone In Preventing Ragweed-Induced Seasonal Allergic Rhinitis (SAR) Symptoms 61st Annual Meeting of the American Academy of Allergy, Asthma and Immunology, San Antonio, TX Kline JN, Casale TB, Busse WW, Ballas ZK, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Moss MH, Bromstead C, Townley RG
    • Transcriptome Seasonal Regulation in Ragweed Allergy 2007 AAAAI Annual Meeting, San Diego, CA Asare AL, Bourcier K, Wang R, Gao Z, Casale TB, Seyfert VL
    • Automated analysis of flow cytometry data for the identification of cellular markers of allergy therapeutic responses Immunology 2010 (97th Annual Meeting of the American Association of Immunologists), Baltimore, MD Casale TB, Scheuermann RH, Qian Y, Kong M, Campbell J, Sadat E, Thomson E, Dunn P, Xiang D, Dahlke CE
    • The combination of anti-IgE monoclonal antibody (omalizumab) with ragweed immunotherapy results in enhanced and long-term inhibitory effects on facilitated-antigen presentation XXVI Meeting of the EAACI, Goteborg, Sweden Francis JN, Saggar LR, Seyfert-Margolis V, Asare AL, Klunker S, Casale TB, Durham SR, Immune Tolerance Network Group
    • Anti-IgE monoclonal antibody administered with immunotherapy (Stanislaus Jaros Lecture) American College of Allergy, Asthma and Immunology (ACAAI), Boston, MA Casale TB
    • Omalizumab pretreatment prevents allergic reactions due to rush immunotherapy (RIT) AAAAI Annual Meeting, San Antonio, TX Casale TB, Kline JN, Busse WW, Ballas ZK, Mokhtarani M, Seyfert-Margolis V, Bateman K, Moss MH, Townley RG
    • Anti-IgE Therapy Inhibits IgE-facilitated Allergen Presentation and Increases the Efficacy of Ragweed Immunotherapy 2006 AAAAI Annual Meeting, Miami, FL Klunker S, Francis JN, Casale TB, Durham SR
    MeSH tags (Click to show/hide)

Peanut

  • Manuscripts and Abstracts

    • Randomized trial of peanut consumption in infants at risk of peanut allergy New Eng J Med DOI: 10.1056/NEJMoa1414850 (2015) Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, Brough HA, Phippard D, Basting M, Feeney M, Turcanu V, Sever ML, Gomez Lorenzo M, Plaut M, Lack G; the LEAP Study Team
    • Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study J Allergy Clin Immunol. 12: S0091-6749, 2012 Du Toit G, Roberts G, Sayre PH, Plaut M, Bahnson HT, Mitchell H, Radulovic S, Chan S, Fox A, Turcanu V, Lack G; Learning Early About Peanut Allergy (LEAP) Study Team
    • Induction Of Tolerance Through Early Introduction Of Peanut In High-Risk Children, The LEAP Study 2010 AAAAI Annual Meeting, New Orleans, LA, February 26 - March 2, 2010 (Abstract #84) Du Toit G, Roberts G, Sayre P, Turcanu V, Fisher HR, Broide D, Nirenstein L, Radulovic S, Stephens A, Seyfert-Margolis V, Nasser N, Murphy S, The Immune Tolerance Network ITN032AD Study Group, Lack G
    MeSH tags (Click to show/hide)

Multiple Allergens

  • Manuscripts and Abstracts

    • Prophylactic use of sublingual allergen immunotherapy in high-risk children: A pilot study J Allergy Clin Immunology, 2013 Holt PG, Sly PD, Sampson HA, Robinson P, Loh R, Lowenstein H, Calatroni A, Sayre P.